New hope for lymphoma patients: CAR T-Cell therapy as Second-Line treatment
NCT ID NCT04531046
First seen Apr 04, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This study tests a treatment called axicabtagene ciloleucel (axi-cel) for people with aggressive B-cell lymphoma that has come back or not responded to treatment. Participants cannot have a standard stem cell transplant but are eligible for this CAR T-cell therapy. The goal is to see if this therapy can control the cancer and lead to a complete response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA REFRACTORY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
APHP - Hôpital Henri Mondor
Créteil, France
-
APHP - Hôpital Saint Louis
Paris, 75475, France
-
CH Liège
Liège, 4000, Belgium
-
CHU Brabois
Vandœuvre-lès-Nancy, 54511, France
-
CHU Clermont Ferrand - Hôpital Estaing
Clermont-Ferrand, France
-
CHU de Bordeaux - Hôpital Haut Lévêque
Bordeaux, France
-
CHU de Dijon - Hôpital le Bocage
Dijon, 21000, France
-
CHU de Nantes - Hôtel Dieu
Nantes, 44093, France
-
CHU de Rennes - Hôpital de Pontchaillou
Rennes, 35003, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Hopital La Pitié Salpétriere
Paris, France
-
Hôpital Claude Huriez
Lille, 59037, France
-
Hôpital Saint Antoine
Paris, France
-
Hôpital Saint Eloi
Montpellier, 34295, France
-
IUCT Oncopole
Toulouse, France
-
Institut de Cancérologie Gustave Roussy
Villejuif, France
Conditions
Explore the condition pages connected to this study.